| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
77,400,000 |
| Market
Cap: |
687.31(M) |
| Last
Volume: |
924,004 |
Avg
Vol: |
1,535,793 |
| 52
Week Range: |
$4.32 - $9.91 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile SIGA Technologies is a commercial-stage pharmaceutical company focused on the health security markets. Co.'s primary product, TPOXX®, is a U.S. Food & Drug Administration-approved oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bayer Michael J |
|
• • – |
2017-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
94,500 |
|
- |
|
| Rose Eric A Md |
Executive Chairman |
• • – |
2017-01-03 |
4 |
D |
$2.93 |
$86,441 |
D/D |
(29,502) |
684,928 |
|
- |
|
| Rose Eric A Md |
Executive Chairman |
• • – |
2017-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
66,667 |
714,430 |
|
- |
|
| Hruby Dennis E |
VP & Chief Scientific Officer |
• • – |
2017-01-03 |
4 |
D |
$2.93 |
$30,510 |
D/D |
(10,413) |
166,411 |
|
- |
|
| Hruby Dennis E |
VP & Chief Scientific Officer |
• • – |
2017-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,000 |
176,824 |
|
- |
|
| Luckshire Daniel J |
Executive VP & CFO |
• • – |
2017-01-03 |
4 |
D |
$2.93 |
$41,105 |
D/D |
(14,029) |
175,714 |
|
- |
|
| Luckshire Daniel J |
Executive VP & CFO |
• • – |
2017-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
33,334 |
189,743 |
|
- |
|
| Luckshire Daniel J |
Executive VP & CFO |
• • – |
2016-12-08 |
4 |
D |
$3.13 |
$77,032 |
D/D |
(24,611) |
156,409 |
|
- |
|
| Luckshire Daniel J |
Executive VP & CFO |
• • – |
2016-12-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
66,668 |
181,020 |
|
- |
|
| Hruby Dennis E |
VP & Chief Scientific Officer |
• • – |
2016-12-08 |
4 |
D |
$3.13 |
$63,539 |
D/D |
(20,300) |
151,824 |
|
- |
|
| Hruby Dennis E |
VP & Chief Scientific Officer |
• • – |
2016-12-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
50,000 |
172,124 |
|
- |
|
| Rose Eric A Md |
Executive Chairman |
• • – |
2016-12-08 |
4 |
D |
$3.13 |
$214,308 |
D/D |
(68,469) |
647,763 |
|
- |
|
| Rose Eric A Md |
Executive Chairman |
• • – |
2016-12-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
133,335 |
716,232 |
|
- |
|
| Slovin Bruce |
|
• • – |
2016-11-16 |
4 |
OE |
$81,250.00 |
$2,147,483,647 |
D/D |
54,167 |
179,167 |
|
- |
|
| Luckshire Daniel J |
Executive VP & CFO |
• • – |
2016-11-16 |
4 |
OE |
$15,000.00 |
$150,000,000 |
D/D |
10,000 |
114,352 |
|
- |
|
| Savas Paul G |
|
• • – |
2016-11-16 |
4 |
OE |
$99,996.50 |
$2,147,483,647 |
D/D |
66,664 |
188,504 |
|
- |
|
| Stern Andrew L |
|
• • – |
2016-11-16 |
4 |
OE |
$1,072.50 |
$766,838 |
D/D |
715 |
62,865 |
|
- |
|
| Marshall Joseph W Iii |
|
• • – |
2016-11-16 |
4 |
OE |
$19,500.00 |
$253,500,000 |
D/D |
13,000 |
88,000 |
|
- |
|
| Kindler Jeffrey B |
|
• • – |
2016-11-16 |
4 |
OE |
$33,508.50 |
$748,546,382 |
D/D |
22,339 |
67,339 |
|
- |
|
| Constance Thomas E |
|
• • – |
2016-11-16 |
4 |
OE |
$50,250.00 |
$1,683,375,000 |
D/D |
33,500 |
248,500 |
|
- |
|
| Macandrews & Forbes Holdings Inc |
Director |
– • • |
2016-11-16 |
4 |
A |
$2.49 |
$1,406,875 |
I/I |
565,010 |
24,156,358 |
|
- |
|
| Macandrews & Forbes Holdings Inc |
Director |
– • • |
2016-11-16 |
4 |
OE |
$1.50 |
$15,090,965 |
I/I |
10,060,643 |
23,591,348 |
|
- |
|
| Antal James |
|
• • – |
2016-11-16 |
4 |
OE |
$45,500.00 |
$1,380,151,500 |
D/D |
30,333 |
111,487 |
|
- |
|
| Bayer Michael J |
|
• • – |
2016-11-16 |
4 |
OE |
$29,250.00 |
$570,375,000 |
D/D |
19,500 |
79,500 |
|
- |
|
| Stern Andrew L |
Director |
– • – |
2016-05-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
62,150 |
|
- |
|
355 Records found
|
|
Page 6 of 15 |
|
|
0.07 (0.79%) 
